Carisma Therapeutics, Inc.
CARM · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Market Cap | $17 | $98 | $491 | $149 |
| - Cash | $18 | $78 | $24 | $29 |
| + Debt | $2 | $3 | $40 | $3 |
| Enterprise Value | $2 | $24 | $507 | $123 |
| Revenue | $20 | $15 | $10 | $27 |
| % Growth | 31.6% | 51.7% | -63% | – |
| Gross Profit | -$40 | -$59 | $10 | $26 |
| % Margin | -204% | -396.8% | 100% | 99.7% |
| EBITDA | -$57 | -$86 | -$56 | -$9 |
| % Margin | -289.5% | -575.7% | -571.4% | -32.1% |
| Net Income | -$60 | -$87 | -$61 | -$0 |
| % Margin | -308.1% | -582.3% | -622.6% | -1.3% |
| EPS Diluted | -1.46 | -2.59 | -1.52 | -1.01 |
| % Growth | 43.6% | -70.4% | -50.5% | – |
| Operating Cash Flow | -$60 | -$81 | -$8 | -$37 |
| Capital Expenditures | -$0 | -$1 | -$5 | -$2 |
| Free Cash Flow | -$60 | -$82 | -$12 | -$39 |